Invesco
TVRD

Invesco’s Tvardi Therapeutics TVRD Stock Holding History

Invesco’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-82,614
Closed -$3.22M – 3902
2025
Q3 		$3.22M Buy
+82,614
New +$2.35M ﹤0.01% 2424
2024
Q2 		– Sell
-471
Closed -$15.4K – 3991
2024
Q1 		$15.4K Hold
471
– – ﹤0.01% 3841
2023
Q4 		$12.6K Sell
471
-262
-36% -$10.8K ﹤0.01% 3811
2023
Q3 		$44.4K Buy
733
+68
+10% +$6.38K ﹤0.01% 3805
2023
Q2 		$67.8K Sell
665
-4,630
-87% -$638K ﹤0.01% 3788
2023
Q1 		$936K Sell
5,295
-134
-2% -$44.9K ﹤0.01% 2930
2022
Q4 		$2.1M Sell
5,429
-2,154
-28% -$818K ﹤0.01% 2634
2022
Q3 		$2.56M Buy
7,583
+392
+5% +$142K ﹤0.01% 2537
2022
Q2 		$2.36M Sell
7,191
-494
-6% -$173K ﹤0.01% 2632
2022
Q1 		$3.36M Sell
7,685
-473
-6% -$194K ﹤0.01% 2567
2021
Q4 		$3.58M Buy
8,158
+2,214
+37% +$1.11M ﹤0.01% 2565
2021
Q3 		$3.31M Sell
5,944
-494
-8% -$248K ﹤0.01% 2590
2021
Q2 		$3.31M Buy
6,438
+6,124
+1,950% +$3.88M ﹤0.01% 2623
2021
Q1 		$246K Buy
+314
New +$215K ﹤0.01% 3625
2017
Q4 		– Sell
-6,479
Closed -$3.19M – 3671
2017
Q3 		$3.19M Buy
6,479
+2,775
+75% +$1.39M ﹤0.01% 2238
2017
Q2 		$2.05M Buy
+3,704
New +$2.35M ﹤0.01% 2533
2016
Q2 		– Sell
-1,401
Closed -$314K – 3726
2016
Q1 		$314K Sell
1,401
-3,733
-73% -$1.12M ﹤0.01% 3426
2015
Q4 		$3.12M Buy
5,134
+254
+5% +$139K ﹤0.01% 2243
2015
Q3 		$2.51M Buy
4,880
+4,866
+34,757% +$3.26M ﹤0.01% 2339
2015
Q2 		$6K Buy
+14
New +$5.41K ﹤0.01% 4140

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Invesco's TVRD Position: Q4 2025 in Review

Invesco sold out of Tvardi Therapeutics (TVRD) in Q4 2025, closing a stake of 82,614 shares — an estimated $3.22M sold.

Invesco first reported a position in TVRD in Q2 2015 and held it in 20 quarters. The position peaked at $3.58M in Q4 2021. 67 funds tracked by Wall St. Rank hold TVRD as of Q4 2025.

  • Invesco reported no remaining Tvardi Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Invesco sold 82,614 Tvardi Therapeutics shares in Q4 2025, an estimated $3.22M.
  • Invesco first reported a position in Tvardi Therapeutics in Q2 2015 and held it in 20 quarters.
  • Invesco's Tvardi Therapeutics position peaked at $3.58M in Q4 2021.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2025.

Based on Invesco's 13F filing for Q4 2025, filed 19 Feb 2026.